Skip to content

Released Mar 27, 2025, before the open

10-K filed Mar 27, 2025, 86 days after period end · 0001576885-25-000049

Q4 2024 · 10-K

derived · Computed from the longer spans the company filed.

Revenue—
Net Income-$37.15MderivedN/M vs Q4 2023N/M vs Q3 2024
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$39,597,000N/M
Operating Cash Flowderived-$27,215,000N/M
Free Cash Flowderived-$27,215,000N/M

What the release said

The release

Same quarter

MetricQ4 2024derived from reported figuresQ4 2023derived from reported figuresQ4 2022derived from reported figuresQ4 2021derived from reported figures
Net Income-$37.15M-$16.50M-$12.87M-$8.35M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Acumen Pharmaceuticals, Inc. · CIK 1576885 · Engraved from SEC EDGAR